Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI

Contributed by: Business Wire

Logo

Tags

Research

Infectious Diseases

Clinical Trials

Biotechnology

General Health

University

Pharmaceutical

Health

Science

Education

Pharmaceutical, Clinical trial, Australia,

More Like This

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery

Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy